Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States
Background: The incidence and prevalence of neuroendocrine neoplasms (NENs) are rapidly rising. Epidemiologic trends have been reported for common NENs, but specific data for lung NENs are lacking. Methods: We conducted a retrospective analysis utilizing the Surveillance, Epidemiology, and End Resul...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/8/1753 |
| _version_ | 1797538620066758656 |
|---|---|
| author | Shrunjal Shah Rohit Gosain Adrienne Groman Rahul Gosain Arvind Dasari Thorvardur R. Halfdanarson Sarbajit Mukherjee |
| author_facet | Shrunjal Shah Rohit Gosain Adrienne Groman Rahul Gosain Arvind Dasari Thorvardur R. Halfdanarson Sarbajit Mukherjee |
| author_sort | Shrunjal Shah |
| collection | DOAJ |
| description | Background: The incidence and prevalence of neuroendocrine neoplasms (NENs) are rapidly rising. Epidemiologic trends have been reported for common NENs, but specific data for lung NENs are lacking. Methods: We conducted a retrospective analysis utilizing the Surveillance, Epidemiology, and End Results (SEER) database. Associated population data were utilized to report the annual age-adjusted incidence and overall survival (OS) trends. Trends for large-cell neuroendocrine carcinoma (LCNEC) and atypical carcinoid (AC) were reported from 2000–2015, while those for typical carcinoid (TC) and small cell lung cancer (SCLC) were reported from 1988–2015. Results: We examined a total of 124,969 lung NENs [103,890—SCLC; 3303—LCNEC; 8146—TC; 656—AC; 8974—Other]. The age-adjusted incidence rate revealed a decline in SCLC from 8.6 in 1988 to 5.3 in 2015 per 100,000; while other NENs showed an increase: TC increased from 0.57 in 1988 to 0.77 in 2015, AC increased from 0.17 in 2001 to 0.22 in 2015, and LCNEC increased from 0.16 in 2000 to 0.41 in 2015. The 5-year OS rate among SCLC, LCNEC, AC, and TC patients was 5%, 17%, 64%, and 84%, respectively. On multivariable analyses, OS and disease-specific survival (DSS) varied significantly by stage, sex, histological type, insurance type, marital status, and race, with a better survival noted in earlier stages, females, married, insured, Hispanic and other races, and urban population. Similarly, TC and AC had better survival compared to SCLC and LCNEC. Conclusion: The incidence of lung NENs is rising, possibly in part because of advanced radiological techniques. However, the incidence of SCLCs is waning, likely because of declining smoking habits. Such population-based studies are essential for resource allocation and to prioritize future research directions. |
| first_indexed | 2024-03-10T12:32:59Z |
| format | Article |
| id | doaj.art-934854c126c94c3b9f3d142fec263c78 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T12:32:59Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-934854c126c94c3b9f3d142fec263c782023-11-21T14:28:30ZengMDPI AGCancers2072-66942021-04-01138175310.3390/cancers13081753Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United StatesShrunjal Shah0Rohit Gosain1Adrienne Groman2Rahul Gosain3Arvind Dasari4Thorvardur R. Halfdanarson5Sarbajit Mukherjee6Department of Medicine/Hematology & Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USADepartment of Medical Oncology and Hematology, UPMC Hillman Cancer Center, UPMC Chautauqua, 207 Foote Avenue, Jamestown, NY 14701, USADepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USADepartment of Medical Oncology and Hematology, Guthrie Corning Cancer Center, Corning, NY 14830, USADepartment of GI Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Oncology, Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55902, USADepartment of Medicine/Hematology & Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USABackground: The incidence and prevalence of neuroendocrine neoplasms (NENs) are rapidly rising. Epidemiologic trends have been reported for common NENs, but specific data for lung NENs are lacking. Methods: We conducted a retrospective analysis utilizing the Surveillance, Epidemiology, and End Results (SEER) database. Associated population data were utilized to report the annual age-adjusted incidence and overall survival (OS) trends. Trends for large-cell neuroendocrine carcinoma (LCNEC) and atypical carcinoid (AC) were reported from 2000–2015, while those for typical carcinoid (TC) and small cell lung cancer (SCLC) were reported from 1988–2015. Results: We examined a total of 124,969 lung NENs [103,890—SCLC; 3303—LCNEC; 8146—TC; 656—AC; 8974—Other]. The age-adjusted incidence rate revealed a decline in SCLC from 8.6 in 1988 to 5.3 in 2015 per 100,000; while other NENs showed an increase: TC increased from 0.57 in 1988 to 0.77 in 2015, AC increased from 0.17 in 2001 to 0.22 in 2015, and LCNEC increased from 0.16 in 2000 to 0.41 in 2015. The 5-year OS rate among SCLC, LCNEC, AC, and TC patients was 5%, 17%, 64%, and 84%, respectively. On multivariable analyses, OS and disease-specific survival (DSS) varied significantly by stage, sex, histological type, insurance type, marital status, and race, with a better survival noted in earlier stages, females, married, insured, Hispanic and other races, and urban population. Similarly, TC and AC had better survival compared to SCLC and LCNEC. Conclusion: The incidence of lung NENs is rising, possibly in part because of advanced radiological techniques. However, the incidence of SCLCs is waning, likely because of declining smoking habits. Such population-based studies are essential for resource allocation and to prioritize future research directions.https://www.mdpi.com/2072-6694/13/8/1753neuroendocrine neoplasmneuroendocrine tumorsbronchial neuroendocrine tumorsincidencesurvivalprognosis |
| spellingShingle | Shrunjal Shah Rohit Gosain Adrienne Groman Rahul Gosain Arvind Dasari Thorvardur R. Halfdanarson Sarbajit Mukherjee Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States Cancers neuroendocrine neoplasm neuroendocrine tumors bronchial neuroendocrine tumors incidence survival prognosis |
| title | Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States |
| title_full | Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States |
| title_fullStr | Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States |
| title_full_unstemmed | Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States |
| title_short | Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States |
| title_sort | incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the united states |
| topic | neuroendocrine neoplasm neuroendocrine tumors bronchial neuroendocrine tumors incidence survival prognosis |
| url | https://www.mdpi.com/2072-6694/13/8/1753 |
| work_keys_str_mv | AT shrunjalshah incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates AT rohitgosain incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates AT adriennegroman incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates AT rahulgosain incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates AT arvinddasari incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates AT thorvardurrhalfdanarson incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates AT sarbajitmukherjee incidenceandsurvivaloutcomesinpatientswithlungneuroendocrineneoplasmsintheunitedstates |